U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma

Jan.21.2021

R & D

U.S. Food and Drug Administration Accepts for Priority Review Application for Opdivo® (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma

　This material is intended to notify the press release issued on January 20 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
　Please click https://www.bms.com/media/press-releases.html for the original press release.

Back to List